Global Market Research Group

"Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. Description- Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012, accounting for 13% of the total number of cancer cases. This figure has been gradually rising with increased smoking and the growing elderly population. Lung cancer is a leading cause of death worldwide, accounting for 1.69 million deaths in 2015. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 a high-risk age range for lung cancer. As the aged population is projected to grow, the prevalence of lung cancer is anticipated to increase, acting as a

Non-Small Cell Lung Cancer Therapeutics Albany, New York, May 05, 2017 "Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. Description- Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 - a high-risk age range for lung cancer. As the aged population is projected to increase, the prevalence of lung cancer is anticipated to increase, thereby acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has cre